Zydus receives final approval from the USFDA for Nystatin and Triamcinolone Acetonide Ointment USP

Deepthi | Myequity news | Date : 12-11-2018 12:00:00 IST

Zydus Cadila has received the final approval from the USFDA to market Nystatin and Triamcinolone Acetonide Ointment USP, (US RLD -Mycolog-ll Ointment), 100,000 units/gram and 1 mg/gram. It will be manufactured at the group's Topical manufacturing facility at Ahmedabad.

It is used to treat fungal skin infections. This product contains nystatin, an anti-fungal drug that works by stopping the growth of fungus. It also contains triamcinolone, an anti-inflammatory corticosteroid that works by reducing swelling, itching, and redness.

About Zydus Cadila:

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 23000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research—based pharmaceutical company by 2020

More from Myequity